New insulin combo aims to tame stubborn diabetes
NCT ID NCT07307235
First seen Jan 03, 2026 · Last updated May 07, 2026 · Updated 22 times
Summary
This study compares a new injectable medication called iGlarLixi against standard diabetes treatments for adults with type 2 diabetes whose blood sugar is not well controlled with oral pills. About 1,316 participants in China will be randomly assigned to receive either iGlarLixi or usual care (basal or premixed insulin). The main goal is to see which approach better lowers blood sugar levels over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.